

## Analyst Highlights Of Week 45/2014

It's time once again to take a look at what happened the past week. The weekly highlights are a great way to catch up, but don't forget that you can watch the full stories from either our front page or the archive sections.

The highlights are compiled from research reports released by leading analyst firms. Please click on the headline to access the summary.

### Healthcare

**Deutsche Bank Initiates Buy On Avanir Pharmaceuticals; Sees 27% Upside For The Stock** - Young  
Avanir Pharmaceuticals (NASDAQ:AVNR), Buy, \$17 PT

**Shares Of Ariad Are Undervalued And Present Upside, Says H.C. Wainwright** - Benjamin  
Ariad Pharmaceuticals (NASDAQ:ARIA), Buy, \$8 PT

**H.C. Wainwright Remains Positive On EDAP Following FDA's Guidance** - Ramakanth  
EDAP TMS S.A. (NASDAQ:EDAP), Buy, \$4.50 PT

**Oppenheimer Comments On Celldex Therapeutics Following 3Q14 Results** - Marai  
Celldex Therapeutics (NASDAQ:CLDX), Outperform, \$36 PT

**Oppenheimer Comments On Intercept As FLINT Manuscript Has Been Accepted For Publication In A Journal** - Felt  
Intercept Pharmaceuticals (NASDAQ:ICPT), Outperform

**Galena Quarterly Update; Oppenheimer Reiterates Perform** - Nochomovitz  
Galena Biopharma (NASDAQ:GALE), Perform

**Oppenheimer Raises ANI Pharmaceuticals Price Target Following Strong 3Q14 Results** - Vanjani  
ANI Pharmaceuticals (NASDAQ:ANIP), Outperform, \$55 PT

**Oppenheimer Comments On Sequenom Following 3Q14 Results** - Jones  
Sequenom (NASDAQ:SQNM), Outperform, \$5 PT

**UPDATE: MLV Initiates Buy On Oxigene; Sees 172% Upside For The Stock** - Zavoico  
Oxigene (NASDAQ:OXGN), Buy, \$6.50 PT

**MLV Reduced MannKind Price Target On A Detailed Review Of The Capital Structure** - Lee  
MannKind Corporation (NASDAQ:MNKD), Hold, \$7 PT

**MLV Maintains Buy On Geron As Full Clinical Hold On Imetelstat Lifted** - Zavoico  
Geron (NASDAQ:GERN), Buy, \$4.25 PT

**MLV Maintains Buy On Galectin Therapeutics; Sees 194% Upside For The Stock** - Bernardino  
Galectin Therapeutics (NASDAQ:GALT), Buy, \$16 PT

**Roth Capital Comments On Sarepta Therapeutics Ahead Of 3Q14 Update** - Chattopadhyay  
Sarepta Therapeutics (NASDAQ:SRPT), Buy, \$22 PT

**Roth Capital Reaffirms Buy On Synta Pharmaceuticals; Sees 844% Upside** - Pantginis  
Synta Pharmaceuticals (NASDAQ:SNNTA), Buy, \$27 PT

**Roth Capital Comments On XOMA Following Initiation Of Two Phase 3 Trials** - Arce  
XOMA (NASDAQ:XOMA), Buy, \$9 PT

**Roth Capital Reiterates Buy On Cytori Therapeutics, \$3.50 PT** - Pantginis  
Cytori Therapeutics (NASDAQ:CYTX), Buy, \$3.50 PT

**Pharmacyclics Quarterly Update; Roth Capital Maintains Buy** - Pantginis  
Pharmacyclics (NASDAQ:PCYC), Buy, \$188 PT

**Maxim Maintains Buy On Galena Following 3Q14 Earnings And Clinical Progress Update** - Kolbert  
Galena Biopharma (NASDAQ:GALE), Buy, \$7 PT

**Maxim Maintains Buy On Achillion Pharmaceuticals Following 3Q14 Update** - Kolbert  
Achillion Pharmaceuticals (NASDAQ:ACHN), Buy, \$22 PT

**Maxim Group Reaffirms Buy On Keryx Biopharmaceuticals Ahead Of Ferric Citrate Launch** - Kolbert  
Keryx Biopharmaceuticals (NASDAQ:KERX), Buy, \$26 PT

**Brean Capital Maintains Buy On Repros Therapeutics Following Analyst Day** - Aschoff  
Repros Therapeutics (NASDAQ:RPRX), Buy, \$41 PT

**Salix: Containing Our Frustration - Seeing Steep Selloff As A Bit Overdone, Says Brean Capital** - Aschoff  
Salix Pharmaceuticals (NASDAQ:SLXP), Buy, \$150 PT

**Cantor Raises Jazz Pharmaceuticals Price Target On Xyrem Scenario Analysis** - Rivkind  
Jazz Pharmaceuticals (NASDAQ:JAZZ), Buy, \$197 PT

## Technology

---

**Cantor Comments On Alibaba Following Earnings Release; Raises PT To \$110** - Squali  
Alibaba Group (NYSE:BABA), Buy, \$110 PT

**Cantor's Naved Khan Comments On Tripadvisor Ahead Of Upcoming Earnings** - Khan  
Tripadvisor (NASDAQ:TRIP), Hold, \$94 PT

**Pixelworks Quarterly Update; Roth Capital Reiterates Buy** - Shankar  
Pixelworks (NASDAQ:PXLW), Buy, \$10 PT

**Oppenheimer Reiterates Perform On Shares Of Sprint Nextel** - Horan  
Sprint Nextel (NYSE:S), Perform

## **Basic Materials**

**Oppenheimer Maintains Pefrom On Exxon Mobil Following 3Q14 Earnings** - Gheit  
Exxon Mobil (NYSE:XOM), **Perform**

## **Industrial Goods**

**Roth Capital Remains Positive On Capstone Turbine Despite Weak FQ2 And Disappointing Outlook** - Koranda  
Capstone Turbine (NASDAQ:CPST), **Buy, \$1.00 PT**

## **Consumer Goods**

**Tesla Motors Quarterly Update; MLV Reiterates Buy** - Driscoll  
Tesla Motors (NASDAQ:TSLA), **Buy, \$300 PT**

## **Financial**

**MLV Maintains Buy On Prospect Capital, Sees 21% Upside** - Nolan  
Prospect Capital (NASDAQ:PSEC), **Buy, \$11.50 PT**

---

### Ratings System Definitions:

**Buy:** Stock is expected to outperform against the market over next 12 months.

**Hold:** Stock is expected to perform in line with the market over next 12 months.

**Sell:** Stock has more downside risk than upside potential at current prices. Expect shares to underperform the market from current prices.

**Outperform:** Stock is expected to outperform within its industry over next 12 months.

**Market Perform/Neutral:** Stock should perform roughly in line with current market. Neither encourages purchase or sale of these securities at current prices.

**Underperform:** Stock's total return is expected to underperform the industry average over next 12 months.

**Overweight:** Stock is expected to perform better than the broad market over next 12 months.

**Equalweight:** Stock is expected to perform in line with broad market over next 12 months.

**Underweight:** Stock is expected to perform worse than broad market over next 12 months.